The aims of our study were to see outcomes of limited core biopsy and compare its outcomes with standard 12-core biopsy in patients with PSA more than 50 ng/dL. We did a retrospective analysis of 149 patients undergoing prostatic biopsy with PSA more than 50 ng/dL between January 2014 and December 2018. Out of 149 patients, 49 underwent limited core (2 to 6 cores) TRUS biopsy with no systemic 12-core biopsy. Other 100 patients underwent standard 12-core biopsy under TRUS guidance. Total of 149 patient's records were analyzed and were included in the final analysis. There was no significant difference in demographics and prostate-specific antigen among the cohorts. All 49 patients in limited core TRUS biopsy had a positive biopsy with no need of re-biopsy. Fourteen out of 100 patients in TRUS biopsy had a negative biopsy. All 14 patients with negative biopsy had an average follow-up of 3.8 years with no conversion to positive biopsy. Patients with PSA more than 50 ng/dL and high clinical suspicion of prostate cancer can undergo limited core biopsy without systemic 12-core biopsy. In patients with no clinical evidence of prostate cancer, 12-core biopsy remains the gold standard for evaluation of prostate cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501352 | PMC |
| http://dx.doi.org/10.1007/s13193-020-01165-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment.
Radiol Imaging Cancer
January 2025
From the Department of Radiology (A.C., A.N.Y., R.E., C.H., G.L., M.M., E.B.J., A.L.C., B.G., G.S.K., A.O.), Sanford J. Grossman Center of Excellence in Prostate Imaging and Image Guided Therapy (A.C., A.N.Y., M.M., A.L.C., B.G.), Department of Surgery, Section of Urology (G.G., L.F.R., P.K.M., S.E.), Department of Pathology (T.A.), and Department of Public Health Sciences (M.G.), University of Chicago, 5841 S Maryland Ave, MC 2026, Chicago, IL 60637.
Purpose To evaluate the use of an automated hybrid multidimensional MRI (HM-MRI)-based tool to prospectively identify prostate cancer targets before MRI/US fusion biopsy in comparison with Prostate Imaging and Reporting Data System (PI-RADS)-based multiparametric MRI (mpMRI) evaluation by expert radiologists. Materials and Methods In this prospective clinical trial (ClinicalTrials.gov registration no.
View Article and Find Full Text PDFHow Many Cores Should Be Collected per Region of Interest in Fusion Targeted Prostate Biopsy? A Retrospective Single Institution Statistical Simulation.
Urology
December 2024
Department of Urology, University of Michigan, Ann Arbor, MI.
Objective: To determine how many cores should be collected per region of interest (ROI) in magnetic resonance imaging-guided fusion prostate biopsy. Magnetic resonance imaging-guided targeted prostate biopsy has led to improved detection of clinically significant prostate cancer (csPC); however, data is limited regarding the optimal number of biopsy cores that should be taken. An ideal number of cores maximizes clinically significant cancer detection while minimizing cost, discomfort, and procedure time.
View Article and Find Full Text PDFThe number of involved regions by prostate adenocarcinoma predicts histopathology concordance between radical prostatectomy specimens and MRI/ultrasound-fusion targeted prostate biopsy.
Front Oncol
December 2024
Department of Urology, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er-Sheva, Israel.
Article Synopsis
- Using MRI-fusion guided prostate biopsy (PB) leads to better agreement with prostatectomy histopathology results compared to traditional 12-core TRUS biopsy, especially in patients with higher-risk prostate cancer.
- In a study involving 218 men diagnosed with prostate cancer, those who underwent MRI-fusion PB had a significantly higher concordance rate (73.1% vs. 42.9%) with the final pathology from surgery.
- The research highlighted that the number of cancer-involved regions in the prostate is an important factor influencing concordance, indicating that MRI-fusion techniques enhance diagnostic accuracy and treatment planning for patients.
The Role of Freehand Transperineal Prostate Biopsy Under Local Anesthesia Without Antibiotics in Outpatient Settings.
Am J Mens Health
December 2024
Department of Urology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Article Synopsis
- The study compared freehand transperineal prostate biopsy (FTPB) and systematic transperineal prostate biopsy (STPB) in patients suspected of having prostate cancer, focusing on their effectiveness, safety, and tolerance.
- Out of 218 patients evaluated, prostate cancer was detected in 129 individuals, with FTPB identifying fewer total cases but a higher rate of clinically significant prostate cancer.
- The findings indicate that FTPB performed under local anesthesia in an outpatient setting is safe, well-tolerated, and serves as an effective alternative to STPB without the need for antibiotics.
Focal therapy using high-intensity focused ultrasound with intraoperative prostate compression for patients with localized prostate cancer: a multi-center prospective study with 7 year experience.
Prostate Cancer Prostatic Dis
November 2024
Department of Pathology, Tokai University Hachioji Hospital, Tokyo, Japan.
Background: To evaluate clinical outcomes of focal therapy using high-intensity focused ultrasound (HIFU) with intraoperative prostate compression for patients with localized prostate cancer (PC).
Methods: Patients were included if they had prostate specific antigen levels of ≤20 ng/mL and clinically significant PC (CSPC) within the left or right half, or upper or lower half of the prostate. CSPC was detected using magnetic resonance imaging-transrectal ultrasound fusion image-guided target biopsy and a 12-core systematic biopsy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!